Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENC · Real-Time Price · USD
6.44
+0.11 (1.74%)
May 15, 2025, 1:17 PM - Market open
Fennec Pharmaceuticals Revenue
Fennec Pharmaceuticals had revenue of $8.75M in the quarter ending March 31, 2025, a decrease of -65.52%. This brings the company's revenue in the last twelve months to $30.91M, down -31.23% year-over-year. In the year 2024, Fennec Pharmaceuticals had annual revenue of $47.54M with 123.69% growth.
Revenue (ttm)
$30.91M
Revenue Growth
-31.23%
P/S Ratio
5.62
Revenue / Employee
$966,000
Employees
32
Market Cap
177.86M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
FENC News
- 2 days ago - Fennec Pharmaceuticals Inc. (FENC) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 - GlobeNewsWire
- 2 months ago - Fennec Pharmaceuticals Inc. (FENC) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025 - GlobeNewsWire
- 3 months ago - Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany - GlobeNewsWire
- 5 months ago - Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales - GlobeNewsWire
- 5 months ago - Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management - GlobeNewsWire